Stromedix, Inc., with Biogen Idec, Inc. (Massachusetts) Roots, Seeks Exit from Regulatory Limbo

Xconomy -- Cambridge, MA-based Stromedix is behind schedule on developing drugs that could stymie a cellular process that causes peoples’ bodies to transplanted kidneys to fail. Yet schedule delays are common in the unpredictable biotech business, and we’re only hearing about this one because of the candid nature of its co-founder and CEO, Michael Gilman.

MORE ON THIS TOPIC